Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
AADI

AADI - Aadi Bioscience, Inc. Stock Price, Fair Value and News

1.92USD-0.05 (-2.54%)Market Closed
Watchlist

Market Summary

USD1.92-0.05
Market Closed
-2.54%

AADI Stock Price

View Fullscreen

AADI RSI Chart

AADI Valuation

Market Cap

48.3M

Price/Earnings (Trailing)

-0.76

Price/Sales (Trailing)

2.08

EV/EBITDA

0.42

Price/Free Cashflow

-0.75

AADI Price/Sales (Trailing)

AADI Profitability

EBT Margin

-260.21%

Return on Equity

-53.65%

Return on Assets

-45.4%

Free Cashflow Yield

-133.63%

AADI Fundamentals

AADI Revenue

Revenue (TTM)

23.3M

Rev. Growth (Yr)

40.38%

Rev. Growth (Qtr)

-3.92%

AADI Earnings

Earnings (TTM)

-63.4M

Earnings Growth (Yr)

-12.63%

Earnings Growth (Qtr)

9.29%

Breaking Down AADI Revenue

Last 7 days

1.6%

Last 30 days

10.5%

Last 90 days

-59.7%

Trailing 12 Months

-83.8%

How does AADI drawdown profile look like?

AADI Financial Health

Current Ratio

6.48

AADI Investor Care

Shares Dilution (1Y)

0.54%

Diluted EPS (TTM)

-2.32

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202318.8M21.5M23.3M0
20224.6M8.2M11.7M15.2M
202111.4M8.8M6.3M3.7M
202000014.0M
20190000
20185.1M10.1M15.1M20.2M
2017158.3K88.6K108.8K93.7K
2016310.1K250.5K190.9K131.3K
2015000369.7K

Tracking the Latest Insider Buys and Sells of Aadi Bioscience, Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 01, 2024
desai neil
sold
-73,269
1.7445
-42,000
executive chairman
Jan 02, 2024
desai neil
sold
-86,549
2.0607
-42,000
executive chairman
Dec 06, 2023
desai neil
sold
-33,914
4.8194
-7,037
executive chairman
Dec 05, 2023
desai neil
sold
-78,940
5.0153
-15,740
executive chairman
Dec 04, 2023
desai neil
sold
-55,986
5.1477
-10,876
executive chairman
Dec 01, 2023
desai neil
sold
-42,881
5.1373
-8,347
executive chairman
Nov 02, 2023
desai neil
sold
-141,105
4.4566
-31,662
executive chairman
Nov 01, 2023
desai neil
sold
-44,644
4.3185
-10,338
executive chairman
Oct 03, 2023
desai neil
sold
-67,303
4.0961
-16,431
executive chairman
Oct 02, 2023
desai neil
sold
-111,698
4.3685
-25,569
executive chairman

1–10 of 39

Which funds bought or sold AADI recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 28, 2024
AMERICAN INTERNATIONAL GROUP, INC.
reduced
-0.4
-22,890
16,285
-%
Feb 26, 2024
Virtu Financial LLC
sold off
-100
-72,000
-
-%
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
reduced
-94.93
-998,000
22,000
-%
Feb 16, 2024
PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO
added
387
7,756
15,756
-%
Feb 15, 2024
MERCER GLOBAL ADVISORS INC /ADV
new
-
37,000
37,000
-%
Feb 15, 2024
Legal & General Group Plc
unchanged
-
-4,185
2,998
-%
Feb 15, 2024
BARCLAYS PLC
added
687
31,000
45,000
-%
Feb 15, 2024
JANE STREET GROUP, LLC
sold off
-100
-51,449
-
-%
Feb 14, 2024
Schonfeld Strategic Advisors LLC
added
6.92
-104,526
84,234
-%
Feb 14, 2024
JANUS HENDERSON GROUP PLC
sold off
-100
-3,780,870
-
-%

1–10 of 47

Are Funds Buying or Selling AADI?

Are funds buying AADI calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AADI
No. of Funds

Unveiling Aadi Bioscience, Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2023
vivo panda, llc
2.1%
509,572
SC 13G/A
Feb 10, 2023
satter muneer a
6.7%
1,630,830
SC 13G/A
Jan 17, 2023
desai neil
10.8%
2,635,196
SC 13D/A
Oct 04, 2022
satter muneer a
5.3%
1,294,785
SC 13G
Sep 26, 2022
avoro capital advisors llc
11.7%
2,849,402
SC 13D/A
Feb 14, 2022
biotechnology value fund l p
2.2%
465,262
SC 13G/A
Feb 14, 2022
venrock healthcare capital partners ii, l.p.
7.3%
1,529,402
SC 13G
Feb 11, 2022
vivo panda, llc
2.8%
575,723
SC 13G/A
Feb 09, 2022
vanguard group inc
3.64%
761,473
SC 13G/A

Recent SEC filings of Aadi Bioscience, Inc.

View All Filings
Date Filed Form Type Document
Feb 12, 2024
S-8
Employee Benefits Plan
Feb 12, 2024
S-3
S-3
Feb 02, 2024
4
Insider Trading
Jan 02, 2024
4
Insider Trading
Dec 14, 2023
8-K
Current Report
Dec 07, 2023
4
Insider Trading
Dec 05, 2023
4
Insider Trading
Dec 01, 2023
144
Notice of Insider Sale Intent

Peers (Alternatives to Aadi Bioscience, Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
36.3B
6.8B
-16.59% -47.80%
-7.7
5.3
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.2B
1.8B
-23.99% -31.71%
-43.66
10.51
76.23% 61.08%
16.4B
2.4B
-4.89% -18.90%
98.05
6.79
15.42% 18.43%
13.3B
3.7B
-7.62% -26.87%
22.19
3.59
8.87% 75.42%
MID-CAP
7.5B
396.6M
-2.06% 34.31%
-14.14
18.84
425.83% 18.94%
6.0B
-
-3.85% 226.12%
-9.63
60.35
54.84% -25.61%
4.0B
240.7M
-19.08% -10.99%
-13.4
16.52
-1.03% -92.09%
3.9B
270.6M
8.92% 47.81%
-16.12
14.25
440.80% -27.84%
3.8B
726.4M
-12.60% 32.37%
-62.48
5.27
40.45% 71.62%
SMALL-CAP
2.0B
398.2M
-3.38% -9.50%
28.08
5.03
85.90% -14.05%
752.9M
983.7M
-9.17% -57.89%
-1.38
0.77
-50.36% 17.16%
217.0M
4.9M
-14.18% -58.18%
-1.32
44.39
-57.57% 50.48%
154.8M
881.7K
289.54% 381.25%
-3.26
112.79
-77.61% -13.74%
4.3M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Aadi Bioscience, Inc. News

Latest updates
Marketscreener.com4 hours ago
InvestorsObserver16 Feb 202408:00 am

Aadi Bioscience, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-3.9%5,959,0006,202,0005,867,0005,227,0004,245,0003,437,0002,307,000-------15,000,00012,500,35710,000,7157,501,0725,001,4292,501,7872,144
Costs and Expenses-7.5%23,808,00025,747,00022,692,00020,698,50019,281,00021,797,00016,121,00016,944,500-87,311,0003,875,0004,207,000---------
Operating Expenses--------15,798,388-87,311,0004,771,3615,602,8635,060,4902,894,0005,744,0874,114,9334,657,2324,966,6385,978,9198,841,2938,868,322
  S&GA Expenses-4.7%11,221,00011,776,00011,207,00011,107,0009,915,00010,006,0009,148,0009,717,500-7,401,000830,000563,000-1,219,203499,0002,195,5152,285,8911,540,7292,160,8452,799,5703,255,0423,619,692
  R&D Expenses-10.7%11,890,00013,315,00010,956,0009,369,5008,773,0007,726,0006,794,0007,227,000-5,754,0003,045,0003,644,0006,279,6932,395,0003,548,5721,829,0422,129,2932,844,6032,264,2555,586,2515,248,630
EBITDA Margin7.4%-2.58-2.79-3.20-3.95-5.32-16.49-25.36-97.61-0.70-0.42-0.29-0.23---------
Interest Expenses0%58,00058,00058,00056,50058,00058,00058,00057,000-157,000227,000224,000230,000229,000-------
Income Taxes-----9,000-9,000----2,000--1,000-------
Earnings Before Taxes9.3%-16,302,000-17,971,000--13,922,000-14,474,000-18,260,000-13,857,000-15,990,000--87,088,000-1,534,000-5,476,000--2,891,000-------
EBT Margin7.4%-2.60-2.81-3.22-3.98-5.35-16.55-25.51-98.29-0.94-0.55-0.39-0.30---------
Net Income9.3%-16,302,000-17,971,000-15,223,000-13,913,000-14,474,000-18,269,000-13,857,000-15,990,000--87,088,000-1,536,000-5,476,0008,020,000-2,892,000-5,282,000-3,324,000-4,446,143-4,647,930-5,683,616-8,492,825-8,518,590
Net Income Margin4.6%-2.73-2.86-3.30-3.98-5.35-16.55-25.51-98.29-23.29-13.72-0.21-0.49---------
Free Cashflow25.2%-13,049,000-17,447,000-22,679,000-11,388,000-8,297,000-10,961,000-19,438,000-12,474,000-17,373,000-17,373,000-3,185,00010,563,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-7.7%14015117118419412914215816937.0041.0019.0050.0046.0036.0040.0046.0050.0055.0064.0070.00
  Current Assets-8.3%13314516518019012413615116237.0041.0019.0050.0045.0035.0040.0045.0049.0054.0064.0070.00
    Cash Equivalents0.9%69.0068.0034.0039.0013511913014916137.0039.004.0047.0045.0035.0039.0043.0048.0053.0063.0069.00
  Inventory4.6%4.003.004.002.001.001.000.00--------------
  Net PPE19.8%4.003.002.001.000.000.000.000.000.00-0.000.000.000.000.000.000.000.000.000.000.00
Liabilities8.3%21.0020.0025.0026.0025.0020.0018.0022.0018.002.002.0031.003.003.003.003.004.004.004.005.00-
  Current Liabilities57.9%21.0013.0018.0019.0018.0013.0012.0015.0012.002.002.0030.003.003.003.003.004.004.004.005.004.00
Shareholder's Equity-10.1%11813114615816910912513615120.0020.0020.0020.0020.0020.0020.0042.0046.0051.0059.0067.00
  Retained Earnings-6.9%-252-236-218-203-189-174-156-142-126-155-150-32.59-141-136-146-142-137-133-127-118-110
  Additional Paid-In Capital0.8%37136836436235828428127927819119020.00189179179179179179178178177
Shares Outstanding0.0%25.0025.0024.0024.0021.0021.0021.0021.005.003.003.003.00---------
Float------178---60.00---49.00---26.00---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations28.7%-11,951-16,758-21,310-11,310-8,195-10,720-19,415-12,428-17,373-3,18510,563-3,275-15,77710,292-3,939-4,865-4,763-5,146-9,078-6,184-6,221
  Share Based Compensation-0.2%3,0493,0542,7402,8702,7572,2351,7811,38364839.0036.00-24534.00308327-786646605622668806
Cashflow From Investing-74.9%12,66750,56116,329-84,379-48,243-241-23.00-46.0025,356----6.83--1*-4.28-119-113-8.53-20.88
Cashflow From Financing-124.0%-75.003138.00-10772,516-87.0029888.00141,717-71.2870.00--------76*6,267
  Dividend Payments----------------------

AADI Income Statement

2023-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Total revenue$ 5,959,000$ 4,245,000$ 18,028,000$ 9,989,000
Operating expenses    
Selling, general and administrative11,221,0009,915,00034,204,00029,069,000
Research and development11,890,0008,773,00036,161,00023,292,000
Cost of goods sold697,000593,0001,882,0001,113,000
Impairment of acquired contract intangible asset0003,724,000
Total operating expenses23,808,00019,281,00072,247,00057,198,000
Loss from operations(17,849,000)(15,036,000)(54,219,000)(47,209,000)
Other income (expense)    
Foreign exchange loss00(3,000)0
Interest income1,605,000620,0004,900,000791,000
Interest expense(58,000)(58,000)(174,000)(173,000)
Total other income (expense), net1,547,000562,0004,723,000618,000
Loss before income tax expense(16,302,000)(14,474,000)(49,496,000)(46,591,000)
Income tax expense000(9,000)
Net loss(16,302,000)(14,474,000)(49,496,000)(46,600,000)
Other comprehensive income (loss):    
Change in unrealized loss on short-term investments28,000(99,000)99,000(99,000)
Comprehensive income (loss)$ (16,274,000)$ (14,573,000)$ (49,397,000)$ (46,699,000)
Net loss per share, basic (in dollars per share)$ (0.60)$ (0.68)$ (1.84)$ (2.21)
Net loss per share, diluted (in dollars per share)$ (0.60)$ (0.68)$ (1.84)$ (2.21)
Weighted-average number of common shares outstanding, basic (in shares)26,946,68321,269,16326,901,81021,052,786
Weighted-average number of common shares outstanding, diluted (in shares)26,946,68321,269,16326,901,81021,052,786
Product sales, net    
Total revenue$ 5,959,000$ 4,245,000$ 18,028,000$ 9,989,000

AADI Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 68,803$ 39,019
Short-term investments50,532133,541
Accounts receivable, net5,7171,862
Inventory3,6151,861
Prepaid expenses and other current assets4,2173,746
Total current assets132,884180,029
Property and equipment, net3,601508
Operating lease right-of-use assets1,2601,522
Other assets1,9142,178
Total assets139,659184,237
Current liabilities:  
Accounts payable2,6053,519
Accrued liabilities11,73214,922
Operating lease liabilities, current portion423394
Due to licensor payable (Note 8)5,7570
Total current liabilities20,51718,835
Operating lease liabilities, net of current portion9461,267
Due to licensor (Note 8)05,757
Total liabilities21,46325,859
Commitments and contingencies (Note 13)
Stockholders’ equity:  
Preferred stock, $0.0001 par value, 10,000,000 shares authorized; no shares issued and outstanding as of September 30, 2023 and December 31, 202200
Common stock, $0.0001 par value; 300,000,000 shares authorized; 24,525,860 and 24,435,007 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively22
Additional paid-in capital370,904361,689
Accumulated other comprehensive loss(16)(115)
Accumulated deficit(252,694)(203,198)
Total stockholders’ equity118,196158,378
Total liabilities and stockholders’ equity$ 139,659$ 184,237
AADI
Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus bound to albumin. The company is also involved in evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.
 CEO
 WEBSITEaadibio.com
 EMPLOYEES89

Aadi Bioscience, Inc. Frequently Asked Questions


What is the ticker symbol for Aadi Bioscience, Inc.? What does AADI stand for in stocks?

AADI is the stock ticker symbol of Aadi Bioscience, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aadi Bioscience, Inc. (AADI)?

As of Thu Feb 29 2024, market cap of Aadi Bioscience, Inc. is 48.32 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AADI stock?

You can check AADI's fair value in chart for subscribers.

What is the fair value of AADI stock?

You can check AADI's fair value in chart for subscribers. The fair value of Aadi Bioscience, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Aadi Bioscience, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AADI so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Aadi Bioscience, Inc. a good stock to buy?

The fair value guage provides a quick view whether AADI is over valued or under valued. Whether Aadi Bioscience, Inc. is cheap or expensive depends on the assumptions which impact Aadi Bioscience, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AADI.

What is Aadi Bioscience, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 29 2024, AADI's PE ratio (Price to Earnings) is -0.76 and Price to Sales (PS) ratio is 2.08. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AADI PE ratio will change depending on the future growth rate expectations of investors.